DDInter112 DDInter119
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Aprepitant {u} (Compound) resembles {v} (Compound) Fosaprepitant
Aprepitant {u} (Compound) binds {v} (Gene) CYP1A2
Aprepitant {u} (Compound) palliates {v} (Disease) colon cancer
Aprepitant {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Aprepitant {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Aprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cannabidiol
Aprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Citalopram
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Toremifene
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Aprepitant {u} may lead to a major life threatening interaction when taken with {v} Deflazacort
Aprepitant (Compound) resembles Fosaprepitant (Compound)
Aprepitant (Compound) binds CYP1A2 (Gene)
Aprepitant (Compound) palliates colon cancer (Disease)
Aprepitant (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class)
Aprepitant (Compound) causes Myocardial infarction (Side Effect)
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Citalopram
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Toremifene
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Aprepitant may lead to a major life threatening interaction when taken with Deflazacort